Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma
Abstract Renal cell carcinoma (RCC) is the most common malignancy of adult human kidney, which accounts for more than 2 % of all cancers. RCC generally does not respond well to conventional chemotherapy and radiotherapy. Cytokine-induced killer (CIK) cells are ex vivo activated lymphocytes with potent activity against various tumors and minimal side effects. Here, we summarize the data on preclinical and clinical efficacy of CIK cells for RCC treatment. Our preclinical data show that CIK cells have potent anti-tumor activity in vitro and in an in vivo nude mouse xenograft model. Clinical studies for the treatment of RCC patients indicate that CIK cell therapy can induce favorable responses with no serious side effects. These studies suggest that CIK cells may become a valuable strategy for the treatment of patients with RCC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Archives of pharmacal research - 37(2014), 5 vom: 02. Apr., Seite 559-566 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Ji Sung [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Clinical study |
|---|
| Anmerkungen: |
© The Pharmaceutical Society of Korea 2014 |
|---|
| doi: |
10.1007/s12272-014-0381-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR024687448 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR024687448 | ||
| 003 | DE-627 | ||
| 005 | 20230519155319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12272-014-0381-x |2 doi | |
| 035 | |a (DE-627)SPR024687448 | ||
| 035 | |a (SPR)s12272-014-0381-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Ji Sung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Pharmaceutical Society of Korea 2014 | ||
| 520 | |a Abstract Renal cell carcinoma (RCC) is the most common malignancy of adult human kidney, which accounts for more than 2 % of all cancers. RCC generally does not respond well to conventional chemotherapy and radiotherapy. Cytokine-induced killer (CIK) cells are ex vivo activated lymphocytes with potent activity against various tumors and minimal side effects. Here, we summarize the data on preclinical and clinical efficacy of CIK cells for RCC treatment. Our preclinical data show that CIK cells have potent anti-tumor activity in vitro and in an in vivo nude mouse xenograft model. Clinical studies for the treatment of RCC patients indicate that CIK cell therapy can induce favorable responses with no serious side effects. These studies suggest that CIK cells may become a valuable strategy for the treatment of patients with RCC. | ||
| 650 | 4 | |a Cytokine-induced killer cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Renal cell carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Preclinical study |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clinical study |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chung, In Sung |4 aut | |
| 700 | 1 | |a Lim, Sang Hee |4 aut | |
| 700 | 1 | |a Park, Yunsoo |4 aut | |
| 700 | 1 | |a Park, Mi Jeong |4 aut | |
| 700 | 1 | |a Kim, Ju Young |4 aut | |
| 700 | 1 | |a Kim, Yong Guk |4 aut | |
| 700 | 1 | |a Hong, Jin Tae |4 aut | |
| 700 | 1 | |a Kim, Youngsoo |4 aut | |
| 700 | 1 | |a Han, Sang-Bae |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of pharmacal research |d Berlin : Springer, 1978 |g 37(2014), 5 vom: 02. Apr., Seite 559-566 |w (DE-627)SPR024670146 |w (DE-600)2106388-6 |x 1976-3786 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2014 |g number:5 |g day:02 |g month:04 |g pages:559-566 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12272-014-0381-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2014 |e 5 |b 02 |c 04 |h 559-566 | ||